Mesa Laboratories, Inc (NASDAQ:MLAB) Poised For Near-Term Rebound On Momentum Signals

Mesa Laboratories shows signs of short-term technical recovery while fundamentals paint a mixed profitability and liquidity picture; valuation by WMDST classifies the stock as fair-valued.

Recent News

On July 3, 2025 the Board declared a regular quarterly dividend of $0.16 per share payable September 15, 2025 to holders of record August 29, 2025.

On July 2, 2025 the company announced timing for its first-quarter fiscal 2026 results release scheduled for August 5, 2025.

On August 18, 2025 Mesa executed a previously announced financing plan, drawing on its credit facility and using proceeds to settle $97.5 million aggregate principal of convertible notes that matured in August 2025.

Technical Analysis

ADX at 21.99 indicates an emerging trend strength; the directional indicators show DI+ at 21.43 moving higher while DI- at 22.72 moves lower, which signals a shift toward bullish directional momentum.

MACD sits at -$1.20 with the MACD line above the signal line at -$2.39 and the MACD trending upward, which constitutes a bullish momentum crossover supporting near-term upside bias.

MRO registers -11.04 with a dip-and-reversal pattern, a negative value that implies the current price sits below the model target and that upward pressure likely exists as the oscillator works toward equilibrium.

RSI at 44.49 and rising portrays improving buying pressure from oversold/neutral levels while remaining below typical overbought thresholds, leaving room for additional near-term gains.

Price closed at $73.14, above the 20-day average of $64.50 and the 50-day average of $69.25 but below the 200-day average of $108.78; that posture supports short-term strength but identifies the 200-day average as a material longer-term resistance level.

Bollinger band narrowness (20-day average $64.50, ±1σ bounds $60.65–$68.35) and a 20-day standard deviation of $3.85 indicate price recently moved above the 1σ upper band; volume today at 1,121,858 far exceeds the 10-day average of 255,287, signaling convective interest accompanying the recent upside.

Ichimoku components place Senkou A at $73.58 and Senkou B at $85.11, with price marginally below Senkou A, which leaves cloud-based resistance nearby; short-term EMAs show a dip-and-reversal on the 12-day EMA, aligning with the MACD crossover and RSI improvement.

Short-term volatility shows a 42-day beta of 4.53 versus a 52-week beta of 1.52, indicating elevated near-term sensitivity relative to the one-year baseline and the need to expect larger intraperiod moves.

 


Fundamental Analysis

Revenue and growth: Total revenue registers $59,543,000. YoY revenue growth shows 234.83% while trailing overall revenue growth reads -4.17%; QoQ revenue growth shows 271.84% per the provided metrics, indicating sizable period-to-period swings in reported growth rates.

Profitability: Gross margin measures 62.04%, operating margin registers 5.15%, and EBIT margin stands at 15.47%. EBIT margin improved QoQ by 222.52% and improved YoY by 33.36%. EBIT at $9,210,000 and EBITDA at $15,167,000 underpin operating profitability despite pressure on operating income noted in the quarter.

Earnings: Reported EPS came in at $1.88 versus an estimate of $2.16, producing an EPS surprise of -12.96%, a shortfall that reduced near-term headline upside despite positive cash flow metrics elsewhere.

Cash flow and liquidity: Operating cash flow measures $1,893,000 with free cash flow of $884,000 and a cash flow margin of 19.12%. Cash on hand equals $21,279,000, while net debt totals $159,905,000, producing a net leverage posture that drove a material financing action in August. The cash conversion cycle sits at 141.82 days, indicating longer working capital duration.

Leverage and coverage: Total debt stands at $197,593,000 with debt-to-equity of 1.145 and debt-to-EBITDA of 13.03; interest coverage measures 4.19x. Management’s August financing and note settlement alter near-term capital structure by replacing convertible notes with drawn credit facility balances.

Returns and efficiency: Return on equity registers 2.75% and return on assets registers 1.09%; asset turnover stands at 0.137. These low returns on capital combine with a high gross margin to indicate concentrated margin capture but modest asset utilization.

Valuation multiples: Trailing PE at 110.38x and forward PE at 59.77x reflect elevated multiple levels; price-to-sales at 7.49x and price-to-book at 2.59x also convey premium valuation characteristics. Enterprise value to revenue equals 10.45 and the enterprise multiple equals 41.03x.

Peer comparisons where available: EBIT margin at 15.47% sits below the industry peer mean of 18.465% and below the industry peer median of 17.478%, and within the industry peer range (low -200.872% to high 33.709%). Book-to-price shows a P/B of 2.59 versus an industry peer mean of 6.29015 and median of 6.86889.

Valuation view: The current valuation as determined by WMDST registers as fair-valued given the mix of high gross margins, low asset turnover, elevated leverage after the financing action, and stretched earnings multiples relative to expected forward earnings.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-06-30
REPORT DATE: 2025-08-05
NEXT REPORT DATE: 2025-11-26
CASH FLOW  Begin Period Cash Flow 27.3 M
 Operating Cash Flow 1.9 M
 Capital Expenditures -1.01 M
 Change In Working Capital -7.95 M
 Dividends Paid -873.00 K
 Cash Flow Delta -6.04 M
 End Period Cash Flow 21.3 M
 
INCOME STATEMENT REVENUE
 Total Revenue 59.5 M
 Forward Revenue 31.7 M
COSTS
 Cost Of Revenue 22.6 M
 Depreciation 1.4 M
 Depreciation and Amortization 6.0 M
 Research and Development 5.0 M
 Total Operating Expenses 56.5 M
PROFITABILITY
 Gross Profit 36.9 M
 EBITDA 15.2 M
 EBIT 9.2 M
 Operating Income 3.1 M
 Interest Income
 Interest Expense 2.2 M
 Net Interest Income -2.20 M
 Income Before Tax 7.0 M
 Tax Provision 2.3 M
 Tax Rate 32.373 %
 Net Income 4.7 M
 Net Income From Continuing Operations 4.7 M
EARNINGS
 EPS Estimate 2.16
 EPS Actual 1.88
 EPS Difference -0.28
 EPS Surprise -12.963 %
 Forward EPS 1.84
 
BALANCE SHEET ASSETS
 Total Assets 435.7 M
 Intangible Assets 285.5 M
 Net Tangible Assets -112.95 M
 Total Current Assets 98.3 M
 Cash and Short-Term Investments 21.3 M
 Cash 21.3 M
 Net Receivables 39.1 M
 Inventory 28.1 M
 Long-Term Investments 18.9 M
LIABILITIES
 Accounts Payable 6.3 M
 Short-Term Debt 101.7 M
 Total Current Liabilities 149.5 M
 Net Debt 159.9 M
 Total Debt 197.6 M
 Total Liabilities 263.2 M
EQUITY
 Total Equity 172.5 M
 Retained Earnings -185.07 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 31.35
 Shares Outstanding 5.501 M
 Revenue Per-Share 10.82
VALUATION
 Market Capitalization 446.0 M
 Enterprise Value 622.4 M
 Enterprise Multiple 41.033
Enterprise Multiple QoQ -47.111 %
Enterprise Multiple YoY -6.259 %
Enterprise Multiple IPRWA high: 123.29
median: 110.415
mean: 94.042
MLAB: 41.033
low: -147.649
 EV/R 10.452
CAPITAL STRUCTURE
 Asset To Equity 2.526
 Asset To Liability 1.655
 Debt To Capital 0.534
 Debt To Assets 0.453
Debt To Assets QoQ 8.284 %
Debt To Assets YoY 5222.3 %
Debt To Assets IPRWA high: 0.843
MLAB: 0.453
mean: 0.299
median: 0.292
low: 0.0
 Debt To Equity 1.145
Debt To Equity QoQ 0.888 %
Debt To Equity YoY 4504.059 %
Debt To Equity IPRWA high: 3.369
MLAB: 1.145
mean: 0.63
median: 0.579
low: -0.395
PRICE-BASED VALUATION
 Price To Book (P/B) 2.586
Price To Book QoQ -37.257 %
Price To Book YoY -30.312 %
Price To Book IPRWA high: 16.759
median: 6.869
mean: 6.29
MLAB: 2.586
low: -5.981
 Price To Earnings (P/E) 110.378
Price To Earnings QoQ -219.57 %
Price To Earnings YoY -10.327 %
Price To Earnings IPRWA high: 249.6
mean: 136.547
median: 121.658
MLAB: 110.378
low: -167.592
 PE/G Ratio -0.669
 Price To Sales (P/S) 7.491
Price To Sales QoQ -29.337 %
Price To Sales YoY -22.087 %
Price To Sales IPRWA high: 73.117
mean: 32.447
median: 24.499
MLAB: 7.491
low: 0.6
FORWARD MULTIPLES
Forward P/E 59.767
Forward PE/G -0.362
Forward P/S 14.056
EFFICIENCY OPERATIONAL
 Operating Leverage -50.116
ASSET & SALES
 Asset Turnover Ratio 0.137
Asset Turnover Ratio QoQ -4.021 %
Asset Turnover Ratio YoY 4.484 %
Asset Turnover Ratio IPRWA high: 0.412
MLAB: 0.137
median: 0.124
mean: 0.121
low: 0.008
 Receivables Turnover 1.47
Receivables Turnover Ratio QoQ -4.67 %
Receivables Turnover Ratio YoY -5.743 %
Receivables Turnover Ratio IPRWA high: 3.133
mean: 1.735
median: 1.672
MLAB: 1.47
low: 0.374
 Inventory Turnover 0.845
Inventory Turnover Ratio QoQ -4.689 %
Inventory Turnover Ratio YoY 30.213 %
Inventory Turnover Ratio IPRWA high: 2.014
MLAB: 0.845
mean: 0.648
median: 0.568
low: 0.084
 Days Sales Outstanding (DSO) 62.096
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 141.822
Cash Conversion Cycle Days QoQ -2.507 %
Cash Conversion Cycle Days YoY -14.671 %
Cash Conversion Cycle Days IPRWA high: 448.876
mean: 170.993
median: 167.784
MLAB: 141.822
low: -175.55
CAPITAL DEPLOYMENT
 Cash Conversion Ratio -1.162
 CapEx To Revenue -0.017
 CapEx To Depreciation -0.719
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 252.0 M
 Net Invested Capital 353.7 M
 Invested Capital 353.7 M
 Net Tangible Assets -112.95 M
 Net Working Capital -51.24 M
LIQUIDITY
 Cash Ratio 0.142
 Current Ratio 0.657
Current Ratio QoQ 4.95 %
Current Ratio YoY -66.2 %
Current Ratio IPRWA high: 19.146
mean: 2.549
median: 1.718
MLAB: 0.657
low: 0.027
 Quick Ratio 0.469
Quick Ratio QoQ -0.49 %
Quick Ratio YoY -65.637 %
Quick Ratio IPRWA high: 12.697
mean: 1.881
median: 1.167
MLAB: 0.469
low: 0.315
COVERAGE & LEVERAGE
 Debt To EBITDA 13.028
 Cost Of Debt 0.784 %
 Interest Coverage Ratio 4.19
Interest Coverage Ratio QoQ 254.196 %
Interest Coverage Ratio YoY 76.5 %
Interest Coverage Ratio IPRWA high: 52.298
mean: 15.464
median: 11.456
MLAB: 4.19
low: -88.481
 Operating Cash Flow Ratio 0.076
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 23.112
DIVIDENDS
 Dividend Coverage Ratio 5.432
 Dividend Payout Ratio 0.184
 Dividend Rate 0.16
 Dividend Yield 0.002
PERFORMANCE GROWTH
 Asset Growth Rate 0.553 %
 Revenue Growth -4.172 %
Revenue Growth QoQ 271.836 %
Revenue Growth YoY 234.831 %
Revenue Growth IPRWA high: 26.158 %
median: 8.281 %
mean: 6.322 %
MLAB: -4.172 %
low: -39.052 %
 Earnings Growth -164.885 %
Earnings Growth QoQ -140.829 %
Earnings Growth YoY 113.314 %
Earnings Growth IPRWA high: 103.125 %
mean: 11.086 %
median: 9.851 %
low: -81.818 %
MLAB: -164.885 %
MARGINS
 Gross Margin 62.038 %
Gross Margin QoQ 0.353 %
Gross Margin YoY -3.119 %
Gross Margin IPRWA high: 91.006 %
median: 63.683 %
mean: 62.189 %
MLAB: 62.038 %
low: -7.085 %
 EBIT Margin 15.468 %
EBIT Margin QoQ 222.519 %
EBIT Margin YoY 33.356 %
EBIT Margin IPRWA high: 33.709 %
mean: 18.465 %
median: 17.478 %
MLAB: 15.468 %
low: -200.872 %
 Return On Sales (ROS) 5.146 %
Return On Sales QoQ 7.298 %
Return On Sales YoY -55.634 %
Return On Sales IPRWA high: 39.857 %
mean: 18.985 %
median: 18.374 %
MLAB: 5.146 %
low: -193.243 %
CASH FLOW
 Free Cash Flow (FCF) 884.0 K
 Free Cash Flow Yield 0.198 %
Free Cash Flow Yield QoQ -88.814 %
Free Cash Flow Yield YoY -88.394 %
Free Cash Flow Yield IPRWA high: 4.685 %
median: 0.712 %
mean: 0.676 %
MLAB: 0.198 %
low: -19.501 %
 Free Cash Growth -92.417 %
Free Cash Growth QoQ 172.947 %
Free Cash Growth YoY 306.693 %
Free Cash Growth IPRWA high: 310.383 %
mean: 85.568 %
median: 14.619 %
MLAB: -92.417 %
low: -376.098 %
 Free Cash To Net Income 0.186
 Cash Flow Margin 19.117 %
 Cash Flow To Earnings 2.4
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.091 %
Return On Assets QoQ -166.769 %
Return On Assets YoY 42.801 %
Return On Assets IPRWA high: 16.404 %
mean: 1.748 %
median: 1.686 %
MLAB: 1.091 %
low: -26.44 %
 Return On Capital Employed (ROCE) 3.217 %
 Return On Equity (ROE) 0.027
Return On Equity QoQ -161.761 %
Return On Equity YoY 22.286 %
Return On Equity IPRWA high: 0.175
median: 0.032
mean: 0.029
MLAB: 0.027
low: -0.524
 DuPont ROE 2.854 %
 Return On Invested Capital (ROIC) 1.761 %
Return On Invested Capital QoQ 152.654 %
Return On Invested Capital YoY -107.434 %
Return On Invested Capital IPRWA high: 5.672 %
median: 2.571 %
mean: 2.222 %
MLAB: 1.761 %
low: -19.888 %

Six-Week Outlook

Near-term momentum favors recovery: MACD crossover, rising RSI, a dip-and-reversal on short EMAs, and increasing DI+ align toward positive price drift from current levels, while a negative MRO suggests upside scope as price trades below modeled target. Elevated volume on recent up-days confirms participation.

Key near-term resistance clusters appear around the Ichimoku Senkou A near $73.58 and the 50-day average near $69.25 (already cleared), with the 200-day average near $108.78 representing a longer runway hurdle. Elevated short-term beta and a widened cash conversion cycle imply greater intraperiod volatility and sensitivity to company announcements and capital-structure developments.

Balance of factors: technicals bias toward a corrective rebound over the next six weeks, fundamentals provide mixed support because of leverage and the recent EPS shortfall, and the August financing action materially alters near-term capital structure dynamics that traders should monitor for follow-through signals.

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. (NASDAQ:MLAB) develops and manufactures a diverse range of life sciences tools and quality control products. Serving markets across North America, Europe, the Asia Pacific, and globally, Mesa Laboratories addresses critical needs in various industries. The Sterilization and Disinfection Control segment provides biological, chemical, and cleaning indicators, essential for evaluating sterilization and decontamination processes in the pharmaceutical, medical device, and healthcare sectors. This segment also extends testing and laboratory services to dental and pharmaceutical industries. In the Clinical Genomics segment, Mesa Laboratories offers the MassARRAY system, a genetic analysis tool, along with consumables like chips, panels, and chemical reagents. These tools support clinical labs in DNA sample analysis for genetic disease testing, pharmacogenetics, oncology, and more. The Biopharmaceutical Development segment delivers automated systems for protein analysis and peptide synthesis, including Gyrolab and PurePep product lines. The Calibration Solutions segment provides quality control products for measuring critical parameters in environmental and process monitoring, as well as medical device and pharmaceutical manufacturing. Products include continuous monitoring systems, dialysate meters, data loggers, and gas flow calibration equipment, marketed under brands such as DialyGuard, ViewPoint, and DataTrace. Established in 1982, Mesa Laboratories is headquartered in Lakewood, Colorado.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.